Perelman School of Medicine, University of Pennsylvania, Department of Radiation Oncology, Philadelphia, Pennsylvania; Mayo Clinic, Department of Radiation Oncology, Phoenix, Arizona.
Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Int J Radiat Oncol Biol Phys. 2019 Jul 1;104(3):553-562. doi: 10.1016/j.ijrobp.2018.12.055. Epub 2019 Jan 6.
The aim of this study was to generate normal tissue complication probability (NTCP) models in patients treated with either proton beam therapy (PBT) or intensity-modulated radiation therapy (IMRT) for oropharynx cancer and to use a model-based approach to investigate the added value of PBT in preventing treatment complications.
For patients with advanced-stage oropharynx cancer treated with curative intent (PBT, n = 30; IMRT, n = 175), NTCP models were developed using multivariable logistic regression analysis with backward selection. For PBT-treated patients, an equivalent IMRT plan was generated to serve as a reference to determine the benefit of PBT in terms of NTCP. The models were then applied to the PBT-treated patients to compare predicted and observed clinical outcomes (calibration-in-the-large). Five binary endpoints were analyzed at 6 months after treatment: dysphagia ≥ grade 2, dysphagia ≥ grade 3, xerostomia ≥ grade 2, salivary duct inflammation ≥ grade 2, and feeding tube dependence. Corresponding toxicity grading was based on National Cancer Institute Common Terminology Criteria for Adverse Events version 4. Paired t tests and Wilcoxon rank tests were used to compare mean NTCP results for endpoints between PBT and IMRT.
NTCP models developed based on outcomes from all patients were applied to those receiving PBT. NTCP values were calculated for the equivalent IMRT plans for all PBT-treated patients, revealing significantly higher NTCP values with IMRT. PBT was associated with statistically significant reductions in the mean NTCP values for each endpoint at 6 months after treatment, with the largest absolute differences in rates of ≥grade 2 dysphagia and ≥grade 2 xerostomia.
NTCP models predict significant improvements in the probability of short-term, treatment-related toxicity with PBT compared with IMRT for oropharyngeal cancer. This study demonstrates an NTCP model-based approach to compare predicted patient outcomes when randomized data are not available.
本研究旨在为接受质子束治疗(PBT)或调强放疗(IMRT)的口咽癌患者建立正常组织并发症概率(NTCP)模型,并采用基于模型的方法研究 PBT 在预防治疗并发症方面的附加价值。
对于接受根治性治疗的晚期口咽癌患者(PBT,n=30;IMRT,n=175),采用多变量逻辑回归分析和向后选择方法建立 NTCP 模型。对于接受 PBT 治疗的患者,生成等效的 IMRT 计划作为参考,以确定 PBT 在 NTCP 方面的获益。然后将这些模型应用于接受 PBT 治疗的患者,以比较预测和观察到的临床结果(大样本校准)。在治疗后 6 个月分析了 5 个二项终点:吞咽困难≥2 级、吞咽困难≥3 级、口干≥2 级、唾液腺炎症≥2 级和需要进食管。相应的毒性分级基于国家癌症研究所不良事件通用术语标准第 4 版。采用配对 t 检验和 Wilcoxon 秩和检验比较 PBT 和 IMRT 之间各终点的平均 NTCP 结果。
基于所有患者的结果建立的 NTCP 模型应用于接受 PBT 治疗的患者。为所有接受 PBT 治疗的患者计算了等效的 IMRT 计划的 NTCP 值,结果显示 IMRT 的 NTCP 值明显更高。PBT 与治疗后 6 个月时各终点的平均 NTCP 值显著降低相关,其中≥2 级吞咽困难和≥2 级口干的发生率差异最大。
与 IMRT 相比,NTCP 模型预测 PBT 治疗口咽癌时短期治疗相关毒性的概率有显著改善。本研究展示了一种基于 NTCP 模型的方法,用于在没有随机数据的情况下比较预测的患者结局。